Doximity’s stock surges on medical AI excitement as analysts debate long-term risks

Doximity, the professional network for physicians, saw its stock explode following fiscal first-quarter 2027 results released on August 6, 2026. Shares more than doubled in premarket trading before settling to close the day with roughly 43% gains. For a company whose stock had been cut in half year-to-date before the announcement, that’s the kind of reversal that makes portfolio managers spill their coffee.

The catalyst was straightforward: AI adoption numbers that actually looked impressive. Doximity reported close to 300,000 quarterly active users on its suite, and nearly half of US doctors at the company’s client hospitals are now engaging with its workflow and scheduling AI tools.

From networking site to AI platform

Doximity has long been described as “LinkedIn for doctors,” a framing that probably undersells what the company has been building. The platform connects over a million medical professionals and has increasingly layered AI-powered tools on top of that network, including clinical decision support, automated scheduling, and documentation assistance.

The company’s AI credentials got a notable boost in July 2026 when a Stanford-Harvard clinical safety study ranked Doximity’s clinical AI above competitors, including models from OpenEvidence.

Before the earnings-driven rally, Doximity’s market capitalization sat at approximately $3.7 billion. That figure reflected a brutal 2026 for the stock, with shares having dropped roughly 50% year-to-date heading into the report. The AI-fueled bounce represented a dramatic sentiment shift, temporarily pushing the stock toward 100% premarket gains before gravity pulled it back to a still-impressive 43% close.

The bull case and the bear trap

The adoption numbers tell a particularly interesting story. Nearly half of US doctors at Doximity’s client hospitals using AI workflow tools suggests the company has crossed the threshold from novelty to utility.

On the other side, at least one analyst raised a concern that deserves attention: Doximity’s AI tools could cannibalize its core medical networking business. The logic isn’t hard to follow. If physicians increasingly come to the platform for AI-powered clinical tools rather than professional networking, the advertising and recruitment revenue models that have historically driven Doximity’s business could erode.

What the numbers actually mean

The 300,000 quarterly active users figure needs context. Doximity claims over a million verified physician members on its platform, meaning roughly 30% of its total user base is actively engaging with the newer product suite.

The question investors should be asking isn’t whether doctors are using the tools. The question is whether Doximity can monetize AI engagement at rates comparable to, or better than, its existing advertising and hiring solutions business.

The broader health-tech AI landscape adds competitive pressure to the picture. Companies like Nuance Communications (owned by Microsoft), Abridge, and Ambience Healthcare are all chasing physician-facing AI tools. Doximity’s advantage is its existing network of verified doctors, a distribution channel that competitors would need years and significant capital to replicate.

The Stanford-Harvard study gives Doximity a temporary edge in the credibility department, though clinical AI benchmarks evolve rapidly.

For investors watching Doximity’s next few quarters, the metrics to track are clear: revenue per user trends, the mix between legacy advertising revenue and AI-driven revenue, and whether the nearly 50% doctor engagement rate at client hospitals continues climbing or plateaus.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.